What is Daclizumab?
This is an immunosuppresant, used to prevent organ rejection in kidney transplant cases. It has also been tested in clinical trials as a treatment for Multiple Sclerosis. Dosing is calculated based on weight and purpose of treatment. More info at: http://www.pdl.com/index.cfm?navId=49
Read more...
Reasons taken & Efficacy
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Slow my MS progress | 5 |
|
|
2 | |||
| Drug trial for MS | 1 | 0 | |||||
| disease-related symptoms | 1 | 0 |
Mouse over the table for more information
Dosages
| 52 mg monthly | ||
|---|---|---|
1
|
||
Stop Reasons
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Other
|
3 | 75% |
|
|
Doctor's advice
|
2 | 50% |
|
|
Did not seem to work
|
1 | 25% |
|
Adherence, Burden & Cost See details from patient evaluations ▼
See more information, including instructions, precautions, side effects, and interactions.
Patient Evaluations
See all 2 patient evaluations
-
- LSK
- Sex: F
- Sensation: Moderate
- Overall: Mild
- Cognition: moderate
- Vision: none
- Speech: mild
- Swallowing: none
- Upper limb: mild
- Walking: mild
- See profile
-
-
- LSK
- 60 mg monthly
- since Mar 01, 2006
-
Efficacy
Slight
for Slow my MS progress
-
Side Effects
None
- See full evaluation
See all 2 patient evaluations
Report created on November 21, 2009.